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Abstract
Rationale Benzodiazepine drugs continue to be prescribed
relatively frequently for anxiety disorders, especially where
other treatments have failed or when rapid alleviation of anx-
iety is imperative. The neuropsychological mechanism by
which these drugs act to relieve symptoms, however, remains
underspecified. Cognitive accounts of anxiety disorders em-
phasise hypervigilance for threat in the maintenance of the
disorders.
Objective and methods The current study examined the ef-
fects of 7- or 8-day administration of diazepam in healthy
participants (n=36) on a well-validated battery of tasks mea-
suring emotional processing, including measures of vigilance
for threat and physiological responses to threat.
Results Compared to placebo, diazepam reduced vigilant–
avoidant patterns of emotional attention (p<0.01) and re-
duced general startle responses (p< .05). Diazepam adminis-
tration had limited effects on emotional processing, enhancing
the response to positive vs negative words in the emotional
categorisation task (p< .05), modulating emotional memory in
terms of false accuracy (p< .05) and slowing the recognition
of all facial expressions of emotion (p= .01).
Conclusions These results have implications for our under-
standing of the cognitive mechanisms of benzodiazepine treat-
ment. The data reported here suggests that diazepam
modulates emotional attention, an effect which may be in-
volved in its therapeutic actions in anxiety.
Keywords Benzodiazepine . Diazepam . Anxiety disorders .
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Introduction
Benzodiazepine drugs were introduced in the 1960s and were
widely used for the treatment of generalised anxiety and panic
disorder. Despite concerns about tolerance and dependence,
benzodiazepines continue to be prescribed quite frequently. In
2008, for example, approximately 5 % of adults in the USA
used a benzodiazepine. Use was greater in the elderly (about
9 %) where the risk of adverse effects such as falls and cog-
nitive impairment is greater (Olfson et al. 2015).
Current guidelines suggest that pharmacological treatment
of anxiety disorders is best provided by antidepressant drugs
such as selective serotonin re-uptake inhibitors (SSRIs), par-
ticularly because patients with anxiety frequently suffer from
co-morbid depressive symptomatology and there is no evi-
dence that benzodiazepines have clinically important antide-
pressant effects when used as monotherapy (Baldwin et al.
2014). However, benzodiazepines can be helpful in anxious
patients unresponsive to antidepressant treatment, and unlike
antidepressant treatment, benzodiazepine administration pro-
duces a rapid alleviation of anxiety apparent from the first
doses of treatment (Burrows and Norman 1999; Baldwin et
al. 2011).
It is therefore important to understand more about the ef-
fects of benzodiazepines on the neuropsychological mecha-
nisms relevant to anxiety disorders. Several studies have ex-
amined the effects of single doses of the benzodiazepine, di-
azepam, on emotional processing in healthy participants,
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finding, for example, somewhat inconsistent effects on the
recognition of emotional faces (Blair and Curran 1999;
Coupland et al. 2003; Zangara et al. 2002; Murphy et al.
2008). There is more consistent evidence that diazepam re-
duces the startle response; however, whether this effect is se-
lective for startle fear potentiation (Bitsios et al. 1999; Patrick
et al. 1996) or instead represents an overall blunting of startle
amplitude is disputed (Abduljawad et al. 1997; Baas et al.
2002; Scaife et al. 2005; Murphy et al. 2008). It is possible
that examination of the effect of repeated dosing of diazepam
might allow more reliable changes on emotional processing to
be elicited.
The aim of the current study was to assess the effects of 7-
day administration of diazepam in healthy participants on rel-
evant tasks of emotional processing using well-validated mea-
sures of facial expression recognition, emotional memory,
threat processing and attentional bias, the latter measured with
a dot probe task. Cognitive accounts have suggested that anx-
iety disorders are associated with vigilant–avoidant patterns of
attention: an initial (automatic) allocation of attention towards
threatening stimuli is followed by a subsequent (strategic)
avoidance (Mogg and Bradley 1998). We therefore explored
the cognitive effects of diazepam on a dot probe task designed
to measure attentional bias to threat at both short (100 ms) and
long (1000 ms) presentation durations.
Participants
Thirty-six healthy participants provided written informed con-
sent and participated in the study which was approved by the
local ethics committee. One participant withdrew from the
study prior to drug administration leaving a total sample of
35 participants (18 female; mean age 22.97 years; range 18–
34 years). Participants had taken no psychotropic medication
for the previous 3 months and were screened to be free of
current or past Axis 1 disorder on the Structured Clinical
Interview for DSM-IV (First et al. 1996). All participants were
judged to be healthy on the basis of a physical examination
(including, as a minimum, measurement of vital signs, auscul-
tation of the heart and chest, abdominal palpation and brief
neurological examination) and medical history. Participants
who were pregnant or lactating, who suffered from dyslexia
or epilepsy and who had a history of drug or alcohol depen-
dency were excluded from the study.
Procedure
Participants were randomly allocated to a double-blind inter-
vention of either a 7- or 8-day administration of 15 mg diaz-
epam or placebo. The daily dose was split to reduce the risk of
adverse effects such as drowsiness. The experimental group
received 5 mg diazepam postprandial in the morning and
10 mg postprandial in the evening for first 5 or 6 days.
Testing took place on days 6 and 7 or 7 and 8, with magnetic
resonance imaging (MRI) data collected on one of the test
days (reported elsewhere) and the emotional processing data
reported here on the other. Only two participants underwent 8-
day administration; this extra day administration was due to
technical problems with the scanner. The order of the test days
was determined by the availability of the MR scanner; there
was no significant difference between the order of the test
days between the groups (placebo, 13 underwent MRI scan
on test day 1; drug, 10 underwent scan on test day 1; X2(1,
n=35)=0.31, p>0.1). On the first day of testing, the partici-
pants were instructed to take their morning dose 1 h prior to
testing and their evening dose as normal; on the second day of
testing (last day of administration), the participants took only
their morning dose and were again instructed to take this 1 h
prior to testing. Diazepam and placebo (lactose) tablets were
identically overencapsulated to ensure blinding. At baseline,
the participants completed the National Adult Reading Test
(NART, Nelson 1982), the trait component of the State and
Trait Anxiety Inventory (STAI, Spielberger et al. 1970) and
the Eysenck Personality Questionnaire (EPQ, Eysenck et al.
1985). The participants completed daily measures of subjec-
tive mood using the Bond and Lader Visual Analogue Scale
(VAS, Bond and Lader 1974), Befindlichkeits Scale (BFS,
von Zerseen et al. 1974) and Positive and Negative Affect
Scale (PANAS, Watson et al. 1988), and day 8 measurements
for the two participants who undertook 8 days of administra-
tion were excluded from analysis. At baseline and on the last
day of administration, the Beck Depression Inventory (BDI,
Beck et al. 1961) and state component of STAI (Spielberger et
al. 1970) were used to assess mood and anxiety. A second
VAS was used to assess subjective state and side effects on
the day of testing (alert, disgust, drowsy, anxious, happy, nau-
sea, sadness).
Emotional task battery
Attentional dot probe task
In this task, emotional faces were paired with neutral faces.
Attentional bias was measured by recording reaction times to
a probe which could be presented either behind the emotional
or neutral faces. The faces were sourced from the JACFEE/
JACNeuF sets of facial expressions (Matsumoto and Ekman
1988). Three types of face pair were presented (neutral–neu-
tral, fearful–neutral and happy–neutral) in equal number (32
of each trial type, 192 trials in total), but only the emotional–
neutral pairings were included in the analysis. Each trial began
with a central fixation cross followed by the presentation of
two faces above and below this point (emotional faces
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appeared with equal frequency above and below). This was
followed by two dots which were presented either vertically
(:) or horizontally (..). For half of the emotional–neutral
pairings, the probe was presented in the same location as the
emotional face. Participants were instructed to press a labelled
key on the keyboard to indicate the orientation of the dots as
quickly and accurately as possible. Eight blocks of 12 short
duration trials in which the face pairs were presented for
100 ms were alternated with eight blocks of 12 long duration
trials in which face pairs were presented for 1000 ms. Median
reaction time and accuracy scores were recorded. Incorrect
trials were excluded from the data analysis. Attentional vigi-
lance scores were calculated for each participant by
subtracting the reaction time from trials when probes appeared
in the same position as the emotional face (congruent trials)
from when probes appeared in the opposite position to the
emotional face (incongruent trials).
Emotion-potentiated startle task
Stimuli Sixty-three pictures of three categories (pleasant, un-
pleasant, neutral) were taken from the International Affective
Picture System (gender-specified, Larson et al. 2000; Lang et
al. 1998). Each picture was presented for 13 s (mean inter-trial
interval= 13 s) on a computer screen. The pictures were pre-
sented in three blocks in a fixed order such that no two of the
same category would appear successively.
Procedure and recording The eyeblink component of the
startle response was recorded from the orbicularis oculi using
electromyography (EMG startle response system, San Diego
Instruments, San Diego, CA, USA). Acoustic probes were 50-
ms, 95-dB bursts of white noise with a nearly instantaneous
rise time (generated through the noise generator and amplifier
of the EMG startle response system) and were delivered bin-
aurally through headphones at 1.5, 4.5 or 7.5 s following
picture onset. To minimise expectation, startle probes were
skipped from two trials per valence per block, and three
probes were given within the inter-trial interval. A practice
session presenting nine neutral pictures and startle probes
was used in the beginning to habituate participants to the star-
tle probes. EMG signals were filtered (low cut-off, 0.5 Hz;
high cut-off, 100 Hz) and rectified. Eyeblink reflex magni-
tudes in microvolts were calculated by subtracting the amount
of integrated EMG at reflex onset from the first peak ampli-
tude of integrated EMG between 20 and 120 ms following
probe onset. Trials with no traceable eyeblink reflex were
assigned a magnitude of zero and included in the analysis.
Trials which were excessively noisy during the 20-ms, pre-
startle baseline period were excluded. Eyeblink magnitudes
were analysed both as raw data and also z-transformed within
subjects to allow comparison of startle magnitudes between
neutral, positive and negative picture valences.
Emotional categorisation and memory
Sixty personality characteristic words selected to be ex-
tremely disagreeable (e.g. domineering, untidy, hostile)
or agreeable (cheerful, honest, optimistic) (taken from
Anderson 1968) were presented on the computer screen
for 500 ms. These words were matched in terms of
word length, ratings of frequency and meaningfulness.
Participants were asked to categorise these personality
traits as likable or dislikable, as quickly and as accu-
rately as possible. Specifically, they were asked to
imagine whether they would be pleased or upset if they
overheard someone else referring to them as possessing
this characteristic, so that the judgement was, in part,
self-referential. Classifications and reaction times for
correct identifications were computed for this task.
Immediately after completion of the categorisation task, the
participants were asked to recall and write down as many of
the personality trait words as possible, and they were given
2 min to do this. This task therefore allowed the assessment of
incidental memory for positive and negative characteristics.
Accuracy and false alarms for positive compared to negatively
valenced stimuli were calculated. Recognition memory was
then assessed by asking participants to respond with a ‘yes’
or ‘no’ to each item on a list containing the 60 targets plus 60
matched distractors (30 positive, 30 negative). Accuracy, re-
action times and false alarms were calculated. Data from one
participant was removed from the recognition task, as their
performance indicated that they had misunderstood the
instructions.
Facial emotion recognition task
The facial expression recognition task featured six basic emo-
tions (happiness, surprise, sadness, fear, anger and disgust)
taken from the Pictures of Affect Series (Ekman and Friesen
1976), which had been morphed between each prototype and
neutral (Young et al. 1997). Briefly, this procedure involved
taking a variable percentage of the shape and texture differ-
ences between the two standard images 0 % (neutral) and
100 % (full emotion) in 10 % steps. Four examples of each
emotion at each intensity were given (total of ten individuals).
Each face was also given in a neutral expression, giving
a total of 250 stimuli presentations. The facial stimuli
were presented on a computer screen (random order) for
500 ms and replaced by a blank screen. Participants
made their responses by pressing a labelled key on the
keyboard. Participants were instructed to classify each
face as being one of either angry, disgusted, fearful,
happy, sad, surprised or neutral, as quickly and as ac-
curately as possible. Accuracy, reaction time and mis-
classifications were measured in this task.
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Analysis
The demographic and baseline characteristics of the two
groups were compared using one-way ANOVA. Subjective
measures of change were compared between the groups using
repeated measures ANOVA with administration as the
between-subjects factor and time (either two levels, baseline
and last day of testing, or seven levels for each day) as the
within-subjects factor. Data from the facial recognition task,
emotional categorisation, emotional memory, dot probe and
emotion-potentiated startle were analysed with repeated mea-
sures ANOVA with administration group as the between-
subjects factor and stimulus valence as the within-subjects
factor. For the dot probe, stimulus duration was an additional
within-subjects factor. As only two participants received 8,
rather than 7-day administration, their responses to daily mea-
sures on day 8 were excluded. The Bond and Lader VASs
were divided into three factors (alertness, contentedness and
calmness) as described by the authors (Bond and Lader 1974).
Three participants did not complete the FERT due to technical
difficulties, and their data is excluded for this task. One subject
in the placebo group had zero accuracy for positive and 27 %
accuracy for negative words on the emotional categorisation
task, indicating that they had failed to understand the task
instructions; we therefore excluded their data from this task.
The data from this subject were comparable to other subjects
in both the subsequent recognition and recall tasks; these data
were therefore not excluded. Technical problems in the
emotion-potentiated startle resulted in the exclusion of data
from seven subjects in the placebo group and ten subjects
from the drug group.
Results
Baseline measures
There were no between-group differences in age, IQ (as mea-
sured by NART), EPQ or the trait component of the STAI (all
p values >0.1, Table 1).
Subjective measures of mood and state
Daily measurements of subjective mood using the PANAS,
BFS and Bond and Lader VAS revealed no absolute group
differences or differences between the groups over time over
the 7 days of administration (all p values >0.1).
Measurements taken at baseline and on the last day of
administration showed no between-group differences in de-
pression [BDI; main effect of group F(1,32)=1.69, p=0.20;
day-by-group interaction F(1,32) = 2.81, p= 0.10] or state
anxiety [STAI; main effect of group F(1,31)=3.24, p=0.08;
trend for placebo group to score lower on state anxiety overall;
day-by-group interaction F(1,31)=0.02, p=0.90; Table 1].
On the day of behavioural testing, the VAS showed that,
compared to placebo, the drug group was significantly more
drowsy (F(1,33)=7.55, p=0.01; Table 1); however, this did
not correlate significantly with any of the measures of emo-
tional processing (all p values >0.05). There were no other
statistically significant differences in subjective state between
the two groups, but there was a tendency for the diazepam
group to be less alert (F(1,33)=3.66, p=0.06, Table 1) and
more sad (F(1,33)=3.78, p=0.06; Table 1) than those receiv-
ing placebo.
Emotional task battery
Attentional dot probe task
An omnibus rmANOVA revealed a duration × valence ×
group interaction (F(1,33)=8.07, p<0.01). Considering each
emotion separately revealed that this three-way interaction
was driven by a group × duration interaction in fearful (F(1,
33) = 9.81, p<0.01), but not happy (p>0.3) faces. Simple
main effect analysis showed that whilst the placebo group
showed vigilance towards fearful faces at the shorter duration
and away from fearful faces at the longer duration, this pattern
was reversed in the diazepam group [simple main effect of
group: long duration, F(1,33)=8.12, p<0.01; short duration
F(1,33)=2.86, p=0.10); simple main effect of duration: pla-
cebo, F(1,33) = 3.06, p= 0.09; diazepam (F(1,33) = 7.26,
p=0.01; Fig. 1].
Emotion-potentiated startle
Diazepam administration reduced the raw startle response
across valences (F(1,16)=5.19, p=0.037, Fig. 2). There were
no between-group differences in the emotional modulation of
the startle in terms of raw response or z scores (all p values
>0.6).
Emotional categorisation and memory
Compared to the placebo group, the diazepam group was sig-
nificantly more accurate at categorising positive compared to
negative personality characteristic words [group × valence
interaction: F(1,32)=5.09, p=0.03; simple main effect of va-
lence within diazepam group: F(1,32)=18.79, p<0.001 and
within placebo group: F(1,32)=0.97, p=0.33; placebo posi-
tive correct mean (SD) 28.81 (1.17) vs negative correct 28.44
(1.41); diazepam 29.17 (1.65) vs 27.61 (2.52)].
Diazepam administration also resulted in faster classifica-
tion of positive vs negative words compared to the placebo
group (group × valence interaction [F(1,32)=4.50, p=0.04;
simple main effect of group for positive words F(1,32)=0.66,
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p=0.42 and for negative words F(1,32)=2.29, p=0.14; sim-
ple main effect of valence for placebo group F(1,32)=5.65,
p=0.02 and for diazepam group F(1,32)=31.51, p<0.001);
placebo positive mean (SD) 922.270 (181.65) vs negative
979.12 (167.30); drug 979.12 (220.94) vs 1101.29 (287.21)].
There were no between-group differences in emotional rec-
ognition memory in terms of accuracy, reaction times or false
alarms (all p values >0.20).
In the emotional recall test, there were no between-group
differences in accuracy (all p values >0.2). In terms of false
accuracy recall, there was a group × valence interaction (F(1,
33)=4.93, p=0.03) with those receiving diazepam recalling
slightly fewer positive vs negative false items, though post
hoc testing on either valence alone failed to reveal group dif-
ferences [simple main effect of group within positive F(1,
33) = 1.96, p=0.17 and negative false recall F(1,33)=1.75,
p=0.20; simple main effect of valence with placebo F(1,
33)=21.25, p<0.001 and diazepam F(1,33)=2.43, p=0.13;
placebo positive mean (SD) 1.59 (1.46) vs negative 0.24
(0.56); drug 0.94 (1.26) vs 0.50 (0.62)].
Facial emotion recognition task
Diazepam administration did not affect accuracy or misclassi-
fication on this task (all p values >0.2). The diazepam group
did, however, perform slower on this task across all of the
emotional expressions [F(1,30)=6.99, p=0.01; placebomean
(SD) 1704.19 ms (340.69) vs drug 1967.93 (217.12)].
Table 1 Baseline and subjective
measures Placebo Diazepam p value
Baseline Last day of
administration
Baseline Last day of administration 1 2
Age 22.41 (3.94) – 23.50 (3.82) – 0.41
IQ (NART) 113.27 (5.71) – 116.84 (5.92) – 0.11
EPQ (N) 5.12 (3.10) – 4.94 (3.12) – 0.87
EPQ (P) 2.82 (2.51) – 3.22 (2.18) – 0.62
EPQ (E) 16.76 (3.60) – 14.94 (3.62) – 0.15
STAI (trait) 27.41 (5.09) – 29.33 (8.23) – 0.41
BDI 1.35 (1.90) 1.53 (1.84) 1.70 (1.90) 2.76 (2.11) 0.20 0.10
STAI (state) 25.13 (3.91) 27.19 (4.43) 28.47 (7.71) 30.76 (7.35) 0.90 0.08
VAS Test day Test day
Alert – 69.65 (16.50) – 56.28 (23.91) 0.06
Disgust – 4.41 (7.24) – 6.06 (9.38) 0.57
Drowsy – 27.00 (21.98) – 48.61 (17.76) 0.01
Anxious – 9.94 (11.98) – 14.61 (17.77) 0.37
Happy – 72.29 (13.20) – 67.78 (16.14) 0.37
Nausea – 5.88 (10.20) – 13.06 (19.79) 0.20
Sadness – 5.82 (4.49) – 15.44 (19.92) 0.06
Table shows means and (standard deviations). p values: 1 = between-group difference, 2 = group × time
interaction
NART National Adult Reading Test (Nelson 1982), EPQ Eysenck Personality Questionnaire (N neuroticism, P
psychoticism, E extroversion; Eysenck et al. 1985), STAI State and Trait Anxiety Inventory (Spielberger et al.





























Fig. 1 Attentional dot probe. Figure shows attentional vigilance scores
[median reaction time (ms) congruent trials–median reaction time (ms)
incongruent trials] for placebo-treated group with 1000-ms stimulus pre-
sentation (black) and 500-ms stimulus presentation (white) and drug-
treated group with 1000-ms stimulus presentation (dark grey) and 500-
ms stimulus presentation (light grey). S short duration, L long duration.
Error bars show standard error. **p< 0.01, denoting simple main effect
of group within long duration at the top of figure and simple main effect
of duration within drug group at the bottom
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Discussion
In this study, 7-day administration with diazepam modulated
attentional vigilance in the dot probe task, specifically revers-
ing an avoidant–vigilant pattern of responding. In addition, we
were able to replicate the finding of reduced startle reactivity
following acute diazepam administration at this longer dosing
regimen. Other effects of the drug on measures of emotional
processing included generalised decreases in speed in facial
expression recognition and decreased positive vs negative
false recall intrusions and are distinct from those previously
identified following antidepressant drug administration on the
same measures.
Vigilance–avoidance accounts of anxiety emphasise ear-
ly (automatic) orienting to threatening stimuli followed by
later (strategic) avoidance of threat (Mogg and Bradley
1998). Both stages are hypothesised to contribute to
anxious symptoms; the initial orienting leads to an
increased probability of attending to threat, while avoid-
ance in the later stages prevents disconfirmation of the
significance of the threat. The effect of benzodiazepine
administration to reduce this vigilant–avoidant pattern of
responding may be related to its anxiolytic properties.
There is evidence that changes in attention to threat can
have subsequent effects on anxious symptoms. For exam-
ple, experimental studies in healthy volunteers have shown
that training attentional biases to threat using modified dot
probe tasks can increase anxious symptoms following a
stress test (MacLeod et al. 2002). Further, in a study
examining the effect of a single session of cognitive
behavioural therapy (CBT) on panic disorder symptoms,
vigilance for threat at a very short duration of presentation
was reduced on the day following administration in the
absence of any changes in symptoms, and this change
predicted subsequent clinical improvement 4 weeks later
(Reinecke et al. 2013). The data from the present study
suggest that diazepam reduced the vigilant–avoidant
pattern of attention for threat, potentially reversing a key
phenotype of anxiety. The increased engagement with
threatening stimuli presented for a longer duration may
therefore reflect a reduction in the ‘threat’ meaning
assigned to the cues following diazepam administration.
An increase in processing threat cues over longer dura-
tions has been suggested to be important for processes
of extinction and habituation in anxiety (Reinecke and
Harmer 2016). However, whether the current profile of
emotional attention following diazepam would facilitate
these secondary processes remains to be assessed.
In a dot probe paradigm designed to measure vigi-
lance to masked happy and fearful faces (mask present-
ed 16 ms after stimulus) and unmasked (100 ms dura-
tion) stimuli, a single dose of diazepam was found to
modulate attentional vigilance in the masked (and pre-
sumably unconsciously processed) condition (Murphy et
al. 2008). In that study, modulation of attention was
found to be driven by increased attention towards happy
faces, an effect which was interpreted as, in fact, the
result of avoidance of neutral faces which may be con-
strued as ambiguous and, therefore, mildly threatening
stimuli (Cooper and Langton 2006). The current task
did not include a masked condition; however, it is
interesting that the pattern of results following the
100-ms stimulus duration following diazepam adminis-
tration in the current study is rather similar to the
pattern seen in the masked condition following a single
dose, with the drug modulating attention away from
fear. Some antidepressant treatments that are also useful
in treating anxiety have also been shown to have effects
on emotional attention. For example, 7-day administra-
tion with citalopram reduced attentional vigilance for
fearful faces in an unmasked (100 ms) but not masked
(16 ms) condition (Murphy et al. 2009). Considering
these findings together suggests similar effects of two
anxiolytic agents with differing pharmacological pro-
files, diazepam and citalopram, in modulating emotional
attention at short stimulus durations. A future study
directly comparing these treatments at all three stimulus
durations would be useful in further exploring these
findings.
In addition to modulating attention to threat, the present
results also replicate the finding of reduced overall startle am-
plitude following diazepam administration. Several other
studies have reported a reduction in baseline startle response
following acute administration (Abduljawad et al. 1997; Baas
et al. 2002; Scaife et al. 2005; Murphy et al. 2008). The fear-
potentiated startle is a well-validated animal model of fear and
















Fig. 2 Emotion-potentiated startle. Figure shows raw startle amplitudes
in microvolts for positive (white), neutral (grey) and negative (black)
pictures. Error bars show standard error. *p< 0.05 for the main effect
of group
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pharmacological manipulations. The emotion-potentiated star-
tle used here is a human analogue of this test where emotional
pictures are used to modulate the emotional context of auditory
startle probes. Although indicative of an anxiolytic response,
the interpretation of a general reduction in startle reactivity
following diazepam administration is difficult, given the drug’s
muscle relaxant and sedative properties, which could conceiv-
ably explain any reduction in reactivity. Interestingly, however,
in a low-dose (5 mg) study in which there were no reported side
effects nor effects on general cognition, a similar reduction in
overall startle reactivity was reported, suggesting that this may
be a direct effect of the drug (Murphy et al. 2008). In the current
study, the expected pattern of increased startle amplitudes to
unpleasant pictures in the placebo group was not very clear,
possibly due to reduced power given the relatively small num-
ber of usable data sets. Moreover, on the day of testing, there
were small differences between the groups on the VASs, sug-
gesting some possible sedating effects of the drug. Taken to-
gether, these factors make the precise interpretation of the cur-
rent results difficult; nonetheless, the data do suggest that re-
peated dosing with diazepam, similar to acute dosing, may
affect baseline startle reactivity.
Evidence for other changes in emotional processing was
more modest. Unlike some previous studies, we found no ev-
idence that diazepammodulated the accuracy of the recognition
of emotional expressions but did find that the drug increased
reaction times across all emotions. Some previous studies using
relatively high (15 mg) acute doses have suggested that diaze-
pam might specifically modulate anger or anger and fear (Blair
and Curran 1999; Zangara et al. 2002), whereas a single lower
(5 mg) dose did not affect the processing of emotional expres-
sions (Murphy et al. 2008). Murphy et al. suggested that diffi-
culty effects might explain findings at higher doses, as there is
evidence to suggest that negative expressions are more difficult
to recognise (Biehl et al. 1997; Russell 1994), and one study
showed general impairment of expression recognition follow-
ing a single dose of 15 mg (Coupland et al. 2003). In two
slightly different paradigms from that used in the present study,
Coupland et al. (2003), like us, found that diazepam slowed
response times to all emotional facial expression. This effect
appears to be non-specific and may reflect the general sedative
properties of the drug.
Some small and inconsistent differences were found in the
categorisation and subsequent recall of emotional personality
descriptors, such that diazepam appeared to facilitate the pro-
cessing of positive vs negative words during categorisation
but disrupt emotional recall in terms of false accuracy in the
opposite direction. It has been argued that it is possible to
distinguish between the cognitive biases apparent in anxiety
and those which are more commonly seen in depression (e.g.
Williams et al. 1988) In particular, biases in emotional mem-
ory are more consistently seen in the context of low mood,
whilst attentional biases and physiological responses to threat
are more common in anxiety. Consistent with this, neuropsy-
chological models of antidepressant drug action emphasise the
importance of early changes in emotional memory as putative
mechanism of action of these drugs (Harmer et al. 2011), and
improvements in positive emotional recall memory following
antidepressant drug administration in healthy participants ap-
pear to be one of the more robust and consistent findings (for a
review, see Harmer et al. 2011). The findings of the current
study further support a distinction between the neurocognitive
effects of treatments that are effective in remediating anxiety
and those which are primarily useful in treating low mood.
The data reported here need to be considered in the light of
some subjective effects on the day of testing. Whilst subjective
measures of mood, anxiety and VASs of subjective feeling
showed no between-group differences over the 7 days of drug
administration, nor were there between-group differences in
depression and anxiety between first and final days of the study,
there were some subtle differences in VAS ratings on the day of
testing. Thesemeasures suggested that on the day of testing, the
participants were more drowsy and tended to be less alert and
more sad, effects which might broadly be considered to be
expected side effects of diazepam administration. The signifi-
cant between-group difference in drowsiness was not signifi-
cantly correlated with any of the emotional processing outcome
measures reported here, but it is possible that some of the spe-
cific effects reported here are secondary to sedative effects of
diazepam that are difficult to fully disentangle.
Taken together, these results suggested that diazepam has a
profile of neurocognitive effects which is distinct from the
effects of antidepressant treatment. In line with cognitive
models of anxiety, diazepam modulated emotional attention
and physiological responses to threat rather than processes
more closely aligned with low mood and antidepressant treat-
ment such as emotional memory. Clinically, these
neurocognitive changes may not only underlie both anxiolytic
effects during treatment, but may also explain reductions in
the efficacy of psychological interventions that have been re-
ported when benzodiazepines are given concomitantly.
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creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
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Creative Commons license, and indicate if changes were made.
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